Daniela Dicenso
Endocrinology, Diabetes & Metabolism · Miami, FLNPI 1194173831
Payments from drug & device makers
Across 138 payments — averaging $23.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$562
- Lilly USA, LLC$428
- Novo Nordisk$279
- Sanofi-aventis U.S. LLC$212
- Tandem Diabetes Care, Inc.$208
- Amgen$190
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,174100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 21 | $562 |
| Lilly USA, LLC | 20 | $428 |
| Novo Nordisk | 14 | $279 |
| Sanofi-aventis U.S. LLC | 12 | $212 |
| Tandem Diabetes Care, Inc. | 6 | $208 |
| Amgen | 6 | $190 |
| Mannkind Corporation | 3 | $164 |
| Abbott | 9 | $155 |
| Dexcom, Inc. | 2 | $123 |
| Tanabe Pharma America, Inc. | 5 | $111 |
| AstraZeneca | 5 | $109 |
| Astellas Pharma US Inc | 6 | $81 |
| Boehringer Ingelheim | 4 | $81 |
| Amneal Pharmaceuticals LLC | 4 | $73 |
| Currax Pharmaceuticals LLC | 4 | $62 |
| Bayer | 2 | $49 |
| Corcept Therapeutics | 2 | $40 |
| Zealand Pharma US, Inc. | 2 | $35 |
| Cequr Corporation | 1 | $33 |
| IBSA Pharma Inc. | 2 | $33 |
| Ascensia Diabetes Care US Inc. | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Lifescan, Inc. | 1 | $21 |
| Recordati_rare_diseases_inc. | 1 | $18 |
| EUSA Pharma (US) LLC | 1 | $18 |
| Radius Health, Inc. | 1 | $16 |
| Vistapharm, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AFREZZA$125
- Omnipod$122
- t:slim X2 Insulin Pump with Control-IQ$115
- AIMOVIG$111
- DEXCOM G6 TRANSMITTER$104
How this compares
$3,186 in reported general payments places this provider in the 45th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 477 | $499,661 |
| DapagliflozinDapagliflozin Propanediol | 1,018 | $388,928 |
| Dapagliflozin-Metformin ErDapaglifloz Propaned/Metformin | 846 | $342,409 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 384 | $244,984 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 258 | $206,747 |
| SynjardyEmpagliflozin/Metformin Hcl | 390 | $195,426 |
| GlyxambiEmpagliflozin/Linagliptin | 129 | $141,547 |
| JardianceEmpagliflozin | 158 | $125,386 |
| TrulicityDulaglutide | 69 | $76,027 |
| Insulin Glargine SolostarInsulin Glargine,hum.Rec.Anlog | 358 | $63,297 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 135 | $60,903 |
| MounjaroTirzepatide | 52 | $59,890 |
| Insulin Glargine Max SolostarInsulin Glargine,hum.Rec.Anlog | 219 | $43,104 |
| Insulin Glargine-Yfgn | 649 | $39,493 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 79 | $37,128 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimTrijardy Xr, Synjardy, Glyxambi, Jardiance, Synjardy Xr | $81 | $783,9351,185 claims |
| Novo NordiskOzempic | $279 | $499,661477 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $212 | $206,747258 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $428 | $135,916121 claims |
| IBSA Pharma Inc.Tirosint | $33 | $6,73540 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Miami
- Rodolfo GalindoMiami$2.5M
- Eugenio Angueira-SerranoMiami$2.2M
- Jay SkylerMiami$2.2M
- Camillo RicordiMiami$1.4M
- Gianluca IacobellisMiami$346K
- Carlos BarreraMiami$157K
- Marilu JuradoMiami$146K
- Richard PratleyOrlando$9.2M
- Jose MandryOcoee$9.1M
- Steven SmithOrlando$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.